Genipin relieves diabetic retinopathy by down-regulation of advanced glycation end products via the mitochondrial metabolism related signaling pathway

Table 1 Active components of Gardenia jasminoides Ellis

MolID	Active component	OB (%)	DL	BBB
MOL009038	GBGB	45.58	0.83	-5.43
MOL001652	1H-2,6-dioxacyclopent(cd)inden-1-one, 4-((acetyloxy)methyl)-5-(beta-D-glucopyranosyloxy)-2a,4a,5,7b-tetrahydro-, (2aS-(2aalpha,5alpha,7balpha))-	26.43	0.71	-2.00
MOL001648	Genipin	26.06	0.10	-0.98
MOL000098	Quercetin	46.43	0.28	-0.77
MOL000422	Kaempferol	41.88	0.24	-0.55
MOL007245	3-Methylkempferol	60.16	0.26	-0.49
MOL001406	Crocetin	35.30	0.26	-0.83
MOL000551	Hederagenol	22.42	0.74	-0.51
MOL003515	(3S,4S,4aR,6aR,6bS,8aS,12aS,14aR,14bR)-3-hydroxy-4,6a,6b,11,11,14b-hexamethyl-1,2,3,4a,5,6,7,8,9,10,12,12a,14,14a-tetradecahydropicene-4,8a-dicarboxylic acid	27.21	0.72	-0.68
MOL013377	Lutein	22.59	0.55	-0.99
MOL009548	Desacetyl asperulosidic acid_qt	32.49	0.10	-1.85
MOL004560	SHANZHISIDE_qt	117.77	0.10	-1.44
MOL001667	Deacetyl asperuloside acid_qt	62.46	0.11	-1.62
MOL007148	Shanzhiside methyl ester_qt	109.77	0.12	-3.18
MOL004555	GARDENOSIDE_qt	52.77	0.12	-0.91
MOL007994	Ilexoside A_qt	22.43	0.74	-0.33

Oral bioavailability ≥ 20%, drug like ≥ 0.1, and brain-blood barrier ≤ -0.30. OB: Oral bioavailability; DL: Drug like; BBB: Brain-blood barrier.

Table 2 Features for signal, chain, modified residue, and glycosylation in SCG3

Type	Position	Description
Signal	1-19	-
Chain	20-468	Secretogranin-3
Modified residue	37	Phosphoserine
Glycosylation1	216	O-linked (GalNAcan) threonine
Glycosylation 2	231	O-linked (GalNAcan) threonine
Glycosylation 3	359	O-linked (GalNAcan) threonine
Modified residue	362	Phosphoserine